News

World Pharma Today || Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

whitepages icon x

Technology Networks | How Can Data Platforms Unlock the Power of Single-Cell Analysis?

Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis

whitepages icon x

flexFS: A File System Transforming the Efficiency of Large-scale Cloud Analytics in Life Sciences and Beyond

Benchmarks highlight a system that’s faster AND cheaper: innovative throughput optimization can deliver over 500x higher aggregate throughput vs. leading elastic solutions, at under half the cost
whitepages icon x

European Pharmaceutical manufacturer || Paradigm4 and Alnylam partnership to accelerate RNAi- based drug discovery

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.